Brufsky, Adam http://orcid.org/0000-0001-8080-7960
Gallagher, Christopher
Funding for this research was provided by:
Pfizer
Article History
Accepted: 30 March 2023
First Online: 6 May 2023
Declarations
:
: This podcast was supported by Pfizer Inc.
: Adam Brufsky has received grants from Agendia and AstraZeneca, and has received consulting fees or honoraria from AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, Seagen, Daiichi Sankyo, Merck, Agendia, Sanofi, and Puma. Christopher Gallagher has received compensation for participation in advisory boards or lectures held by AstraZeneca, Daiichi Sankyo, Lilly Oncology, and Pfizer (Pfizer participation was limited to serving as an advisory board member for a Health Equity Initiative in Underserved Patient Populations with Metastatic Breast Cancer).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.